Life Sciences
Amgen Looks Ready for an Upside Breakout
Traders could go long at current levels risking below $240 for now.
Novocure Enters a New 'Phase'
Here is where aggressive traders could go long the cancer therapy name.
Exact Sciences Has 2 Strategies - Bullish Fundamentals but Bearish Charts
The charts suggest further weakness is possible.
Looking at Bristol-Myers Again as the Quants Downgrade It
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
2 Long-Term Bargains Emerge in Biotech
Karyopharm Therapeutics and Gamida Cell are promising companies that have seen their shares pull back significantly in recent weeks.
Let's Take Another Look at Halozyme Therapeutics
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead.
Emergent BioSolutions Turns Bearish, So Beware
A break in a key support level could precipitate further declines in the life sciences company's shares.
Tighten Your Sell Stops on Edwards Lifesciences
Let's take a look at the charts and indicators.
NantKwest's Charts Are Extended When Compared to the Popular Moving Averages
Let's stand aside for now and see how things unfold.
NovoCure Has Broken Down on the Charts: What to Do Now
Our latest analysis and trading strategy on NVCR.